Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Advanced Carcinoma of Unknown Primary Origin: A Reasonable Regimen for the Community-Based Clinic?
- 1 January 2007
- journal article
- research article
- Published by Informa UK Limited in Cancer Investigation
- Vol. 25 (1), 27-31
- https://doi.org/10.1080/07357900601130656
Abstract
Optimal treatment for cancer of unknown primary (CUP) can challenge clinicians. This study sought to determine the efficacy and toxicity of weekly paclitaxel and carboplatin in CUP. Forty-two subjects enrolled. Treatment was intravenous paclitaxel (80 mg/m2) plus carboplatin (AUC = 2) on Days 1, 8, and 15 every 28 days. Seven (18 percent) responded (complete = 2, partial = 5); median survival was 8.5 months; estimated survival (12 and 24-month) was 33 and 17 percent, respectively. Median time to progression was 3.7 months, and estimated progression-free survival (12 and 24 months) was 14 and 7 percent, respectively. Median duration of response was 17.3 months. This combination produced modest antitumor activity in advanced CUP.Keywords
This publication has 8 references indexed in Scilit:
- Cancer of unknown primary: clinicopathologic correlationsAPMIS, 2003
- Cisplatin in Combination With Either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study—Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)Journal of Clinical Oncology, 2003
- Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary SiteJournal of Clinical Oncology, 2002
- Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network StudyJournal of Clinical Oncology, 2002
- Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group StudyJournal of Clinical Oncology, 2000
- Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.Journal of Clinical Oncology, 1997
- Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning systemInvestigational New Drugs, 1995
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958